Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Yohannes T, Ghebre"'
Autor:
Afshin Ebrahimpour, Manisha Ahir, Min Wang, Anil G. Jegga, Mark D. Bonnen, N. Tony Eissa, Sydney B. Montesi, Ganesh Raghu, Yohannes T. Ghebre
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology. Currently, pirfenidone and nintedanib are the only FDA-approved drugs for the treatment of IPF and are now the standard of care. This is a signi
Externí odkaz:
https://doaj.org/article/3ce6a0a83e064759a2ff579276fe6229
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Historically, the effort by academia and industry to develop new chemical entities into lifesaving drugs has limited success in meeting the demands of today’s healthcare. Repurposing drugs that are originally approved by the United States Food and
Externí odkaz:
https://doaj.org/article/5f7302f5a32948c5ab807c19e6730d2d
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
This review article outlines six molecular pathways that confer resistance of cancer cells to ionizing radiation, and describes how proton pump inhibitors (PPIs) may be used to overcome radioresistance induced by alteration of one or more of these si
Externí odkaz:
https://doaj.org/article/66dff6de1c19474ba5b14a3b6a2381bb
Autor:
Afshin Ebrahimpour, Min Wang, Li Li, Anil G. Jegga, Mark D. Bonnen, N. Tony Eissa, Ganesh Raghu, Soma Jyothula, Farrah Kheradmand, Nicola A. Hanania, Ivan O. Rosas, Yohannes T. Ghebre
Publikováno v:
Journal of Inflammation, Vol 18, Iss 1, Pp 1-14 (2021)
Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is an orphan disease characterized by progressive loss of lung function resulting in shortness of breath and often death within 3–4 years of diagnosis. Repetitive lung injury in susceptible
Externí odkaz:
https://doaj.org/article/e4e7d799ccab4aaabac4af93292863d5
Autor:
Yohannes T. Ghebre
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/3d2a1f7230ea45bbbec5ec7aba4b011f
Publikováno v:
Cell Reports, Vol 15, Iss 5, Pp 919-925 (2016)
Efficient nuclear reprogramming of somatic cells to pluripotency requires activation of innate immunity. Because innate immune activation triggers reactive oxygen species (ROS) signaling, we sought to determine whether there was a role of ROS signali
Externí odkaz:
https://doaj.org/article/065786a63df8434e8bfed867cf2e90f0
Autor:
Yohannes T. Ghebre
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The recent FDA approval of two drugs, pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF) has fueled interest in the development of additional drugs to treat the disease or its major clinical complications including c
Externí odkaz:
https://doaj.org/article/700dc180849f40878e47c806e076b743
Autor:
Shubham Dubey, Praveen K. Dubey, Channakeshava S. Umeshappa, Yohannes T. Ghebre, Prasanna Krishnamurthy
Publikováno v:
J Cell Physiol
Pathological fibrosis contributes to progression of various diseases, for which the therapeutic options are limited. Idiopathic pulmonary fibrosis (IPF) is one such progressive and fatal interstitial fibrotic disease that is often characterized by ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799b4f3dc1d2d46477c3884581ecaab0
https://doi.org/10.1002/jcp.30684
https://doi.org/10.1002/jcp.30684
Autor:
Wangjie Yu, Cristian Coarfa, Ananth Annapragada, Min Wang, Tej K. Pandita, Ratna Veeramachaneni, Vlad C. Sandulache, Sandra L. Grimm, Sergio Jaramillo, Michelle Ludwig, Kassidy A. Hebert, Mark D. Bonnen, Yohannes T. Ghebre, Farrah Kheradmand, David B. Corry, George Miles, Andrew G. Sikora, Shixia Huang, Dimuthu Perera, Raj K. Pandita
Publikováno v:
Oncotarget
The resistance of cancer cells to radiation-based treatment is a major clinical challenge confounding standard of care in cancer. This problem is particularly notable in many solid tumors where cancer cells are only partially responsive to radiation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dafb267ca42b6718c0ec02ed30204e5c
http://europepmc.org/articles/PMC8274720
http://europepmc.org/articles/PMC8274720
Autor:
Alexander N. Hanania, Walker Mainwaring, Nicola A. Hanania, Yohannes T. Ghebre, Michelle Ludwig
Publikováno v:
Chest. 156:150-162
Radiation-induced lung injury (RILI) encompasses any lung toxicity induced by radiation therapy (RT) and manifests acutely as radiation pneumonitis and chronically as radiation pulmonary fibrosis. Because most patients with thoracic and breast malign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::575d23694eefb61bca8bc727a7f528f5
https://doi.org/10.1016/j.chest.2019.03.033
https://doi.org/10.1016/j.chest.2019.03.033